I'm not sure if Mr Bayrou has a realistic chance of being elected, to be honest, but with so many French voters still undecided, nothing is certain at this stage.
Late Tuesday afternoon, the companies presented mediocre trial results showing that bapineuzumab (b-mab for short) didn't work overall in an 18-month second stage trial but seemed to help a subset of patients who lack a certain gene mutation, APOE4.